Results 271 to 280 of about 355,010 (330)

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A combination of nucleotide hepatitis C virus (HCV) nonstructural protein (NS) 5B and 5A inhibitors is a preferred standard of care for treating chronic HCV. Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against HCV NS5B.
Xiao‐Jian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Janet Hammond   +7 more
wiley   +1 more source

Silver Nanoparticles-Functionalized Textile against SARS-CoV-2: Antiviral Activity of the Capping Oleylamine Molecule. [PDF]

ACS Appl Mater Interfaces
de Souza TB, Rosa AS, Constantino-Teles P, Ferreira VNS, Archanjo BS, Soares CAG, Picciani PHS, Allão Cassaro RA, Miranda MD, Poneti G.   +9 more
europepmc   +1 more source

Drug‐Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources

Clinical Pharmacology &Therapeutics, EarlyView.
Adverse drug reactions (ADRs) are a common cause of morbidity and mortality in hospitalized patients. Identification of ADRs in clinical practice, surveillance and research is essential to prevent further harm. The aim of this study was to assess the likelihood of drugs contributing to clinically important inpatient adverse events, in order to provide ...
Anna Maria Wermund, Annette Haerdtlein, Wolfgang Fehrmann, Clara Weglage, Tobias Dreischulte, Ulrich Jaehde   +5 more
wiley   +1 more source

Prodigiosin Demonstrates Promising Antiviral Activity Against Dengue Virus and Zika Virus in In-silico Study. [PDF]

Anal Sci Adv
Rahman T, Bappi MSH, Hossain TJ.
europepmc   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source

Antiviral activity of cathelicidins against porcine epidemic diarrhea virus (PEDV): Mechanisms, and efficacy. [PDF]

Virus Res
Pashaie F, Hoornweg TE, Bikker FJ, Veenendaal T, Broere F, Veldhuizen EJA.   +5 more
europepmc   +1 more source

Sustainable Synthesis of 1,2,3‐Triazoles using Cyrene as a Biodegradable Solvent in Click Chemistry

ChemSusChem, EarlyView.
Green triazoles: The first successful synthesis of 1,2,3‐triazoles using Cyrene as a biodegradable and non‐toxic solvent in click chemistry has been developed. This sustainable approach allows product isolation by simple precipitation in water, eliminating the need for organic solvent extractions and chromatographic purifications, thus minimizing waste
Andrea Citarella, Alessandro Fiori, Alessandra Silvani, Daniele Passarella, Valerio Fasano   +4 more
wiley   +1 more source

Structural and functional characterization of the KHNYN extended-diKH domain for mediating ZAP antiviral activity

Youle RL, Lista MJ, Bouton C, Kunzelmann S, Wilson H, Cottee MA, Purkiss AG, Morris ER, Neil SJD, Taylor IA, Swanson CM.   +10 more
europepmc   +1 more source

Discovery of a novel inhibitor of macropinocytosis with antiviral activity. [PDF]

Mol Ther
Porebski B, Christ W, Corman A, Haraldsson M, Barz M, Lidemalm L, Häggblad M, Ilmain J, Wright SC, Murga M, Schlegel J, Jarvius M, Lapins M, Sezgin E, Bhabha G, Lauschke VM, Carreras-Puigvert J, Lafarga M, Klingström J, Hühn D, Fernandez-Capetillo O.   +20 more
europepmc   +1 more source